TCL Archive ESA Risk Mitigation Strategy Requires Training, Patient Consent, Documentation February 19, 2010
TCL Archive In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List December 2, 1983